

Nancy K Sweitzer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11531622/nancy-k-sweitzer-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

5,293
citations

33
h-index

72
g-index

87
ext. papers

6,819
ext. citations

7.5
avg, IF

5.1
L-index

#	Paper	IF	Citations
75	Spironolactone for heart failure with preserved ejection fraction. <i>New England Journal of Medicine</i> , 2014 , 370, 1383-92	59.2	1365
74	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. <i>Circulation</i> , 2015 , 131, 34-42	16.7	534
73	High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. <i>Circulation: Heart Failure</i> , 2011 , 4, 180-7	7.6	268
72	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015 , 132, 402-14	16.7	263
71	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016 , 37, 455-62	9.5	217
70	Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 104-15	7.6	174
69	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 740-51	7.6	159
68	Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. <i>Circulation</i> , 2014 , 129, 2380-7	16.7	158
67	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9, e002763	7.6	147
66	Multiple biomarkers for risk prediction in chronic heart failure. <i>Circulation: Heart Failure</i> , 2012 , 5, 183-90	7.6	145
65	Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1165-72	15.1	139
64	Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. <i>Circulation: Heart Failure</i> , 2013 , 6, 184-92	7.6	122
63	Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (. <i>American Journal of Cardiology</i> , 2008 , 101, 1151-6	3	105
62	Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. <i>Circulation</i> , 2009 , 120, 310-7	16.7	91
61	Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. <i>Circulation: Heart Failure</i> , 2018 , 11, e005266	7.6	79
60	Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 2456-61	11.5	78
59	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70

58	Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 228-238	7.9	62
57	Strain improves risk prediction beyond ejection fraction in chronic systolic heart failure. <i>Journal of the American Heart Association</i> , 2014 , 3, e000550	6	56
56	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1570-1577	15.7	56
55	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). <i>Circulation</i> , 2017 , 136, 982-992	16.7	55
54	The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 386-94	15.1	55
53	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015 , 8, 1052-8	7.6	54
52	Does Race Influence Decision Making for Advanced Heart Failure Therapies?. <i>Journal of the American Heart Association</i> , 2019 , 8, e013592	6	52
51	Acute decompensated heart failure: update on new and emerging evidence and directions for future research. <i>Journal of Cardiac Failure</i> , 2013 , 19, 371-89	3.3	49
50	Decreased cardiac functional reserve in heart failure with preserved systolic function. <i>Journal of Cardiac Failure</i> , 2011 , 17, 301-8	3.3	44
49	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 689-697	7.9	36
48	Association of Gender and Race With Allocation of Advanced Heart Failure Therapies. <i>JAMA Network Open</i> , 2020 , 3, e2011044	10.4	36
47	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1596-1604	12.3	35
46	Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 653-661	7.9	34
45	Increases in central aortic impedance precede alterations in arterial stiffness measures in type 1 diabetes. <i>Diabetes Care</i> , 2007 , 30, 2886-91	14.6	34
44	Cardiology patient page. What is an angiotensin converting enzyme inhibitor?. <i>Circulation</i> , 2003 , 108, e16-8	16.7	34
43	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018 , 24, 313-320	3.3	33
42	Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. <i>Circulation: Heart Failure</i> , 2018 , 11, e005008	7.6	33
41	Decreased immune responses to influenza vaccination in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2009 , 15, 368-73	3.3	31

40	Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016 , 22, 256-62	3.3	30
39	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2015 , 21, 674-93	3.3	28
38	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 664-675	7.9	28
37	Factors Related to Physician Clinical Decision-Making for African-American and Hispanic Patients: a Qualitative Meta-Synthesis. <i>Journal of Racial and Ethnic Health Disparities</i> , 2018 , 5, 1215-1229	3.5	25
36	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 1000-1005	16.2	24
35	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e005288	7.6	23
34	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004457	7.6	20
33	Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. <i>Journal of Cardiac Failure</i> , 2014 , 20, 569-76	3.3	20
32	Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. <i>European Journal of Heart Failure</i> , 2013 , 15, 560-4	12.3	20
31	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 483-490	12.3	17
30	Effect of renal function on prognosis in chronic heart failure. <i>American Journal of Cardiology</i> , 2015 , 115, 62-8	3	15
29	Decreased T-cell responses to influenza vaccination in patients with heart failure. <i>Pharmacotherapy</i> , 2010 , 30, 10-6	5.8	14
28	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019 , 123, 611-617	3	14
27	Lack of persistence of influenza vaccine antibody titers in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2014 , 20, 105-9	3.3	12
26	Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1288-1291	12.3	11
25	Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. <i>American Journal of Cardiology</i> , 2016 , 118, 1855-1860	3	11
24	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006125	7.6	10
23	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 714-21	5.8	9

22	Is the Affordable Care Act Medicaid Expansion Linked to Change in Rate of Ventricular Assist Device Implantation for Blacks and Whites?. <i>Circulation: Heart Failure</i> , 2020 , 13, e006544	7.6	6
21	Left ventricular responses to acute changes in late systolic pressure augmentation in older adults. <i>American Journal of Hypertension</i> , 2013 , 26, 866-71	2.3	6
20	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 815-816	12.3	5
19	Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients. <i>Circulation</i> , 2021 , 143, 2412-2414	16.7	5
18	Nonmalignant diagnoses in patients. Case 3. Right atrial thrombus associated with a central venous catheter in a patient with metastatic adrenocortical carcinoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2638-9	2.2	4
17	Heart Transplantation Survival and the Use of Traumatically Brain-Injured Donors: UNOS Registry Propensity-Matched Analysis. <i>Journal of the American Heart Association</i> , 2019 , 8, e012894	6	3
16	Determinants of exercise intolerance in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2547-8; author reply 2548-9	15.1	3
15	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 557-559	12.3	3
14	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021 , 14, e008293	7.6	2
13	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 1022-1028	7.9	2
12	Imbalance in Heart Transplant to Heart Failure Mortality Ratio by Sex. <i>Journal of the American Heart Association</i> , 2021 , 10, e020146	6	2
11	When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data Interpretation. <i>Circulation: Heart Failure</i> , 2018 , 11, e005116	7.6	1
10	Choosing a Career in Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e006139	7.6	1
9	Continuing Medical Education Activity in Echocardiography. <i>Echocardiography</i> , 2013 , 30, 512-512	1.5	1
8	Is the Affordable Care Act Medicaid Expansion Associated with Receipt of Heart Failure Guideline-Directed Medical Therapy By Race and Ethnicity?. <i>American Heart Journal</i> , 2021 , 244, 135-135	4.9	1
7	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018 , 3, 319-329	1.6	1
6	Sex Disparities in Organ Donation: Finding an Equitable Donor Pool. <i>Journal of the American Heart Association</i> , 2021 , 10, e020820	6	1
5	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 205-217	4	0

4	The association between heart rate behavior and gait performance: The moderating effect of frailty.. <i>PLoS ONE</i> , 2022 , 17, e0264013	3.7	o
3	Re: Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2009 , 15, 549-551	3.3	
2	Grace Under Pressure.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE122009513	7.6	
1	2021: A Look Back.. <i>Circulation: Heart Failure</i> , 2021 , 14, e009358	7.6	